[Osimertinib (Tagrisso(®)): Activity, indication and modality of use in non-small cell lung cancer].

[Osimertinib (Tagrisso(®)): Activity, indication and modality of use in non-small cell lung cancer].

Bull Cancer. 2016 Sep 15;

Authors: Giroux Leprieur E, Cortot AB, Cadranel J, Wislez M

Abstract
The acquisition of a resistance EGFR mutation in exon 20 (T790M) occurs in half of the cases of secondary resistance to EGFR tyrosine kinase inhibitors (TKI), given in first-line treatment in advanced EGFR-mutated non-small cell lung cancers (NSCLC). Osimertinib (AZD9291, Tagrisso(®)) is a third-generation, irreversible EGFR TKI, active in case of T790M mutation. A large phase I trial showed the efficacy of osimertinib after failure of first-generation EGFR TKI (erlotinib, gefitinib), with response rate at 51% and up to 61% in case of T790M mutation. Progression-free survival was 9.6 months in case of T790M. Toxicity profile was acceptable, with mainly digestive (diarrhea) and skin (rash) side effects. Preliminary data from a phase II trial confirmed these efficacy and safety data. Screening of T790M mutation at the time of progression with TKI can be performed in circulating tumor DNA in plasma, with good diagnostic performances.

PMID: 27641462 [PubMed - as supplied by publisher]

from Cancer via ola Kala on Inoreader http://ift.tt/2cMJod5
via IFTTT